(15008931), J. S. W., (15054769), H. T., (15054772), J. A. E., (15054775), N. M. A., (15054778), B. S., (15054781), H. B., . . . (14932995), M. A. D. (2025). Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
Čikaški stil citiranja (17. izdanje)(15008931), James S. Wilmott, et al. Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib Plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. 2025.
MLA način citiranja (9. izdanje)(15008931), James S. Wilmott, et al. Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib Plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. 2025.